Eleven Biotherapeutics Inc (NASDAQ:EBIO) is scheduled to announce its earnings results on Wednesday, March 22nd.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) opened at 1.94 on Tuesday. Eleven Biotherapeutics Inc has a 12-month low of $0.28 and a 12-month high of $5.97. The stock’s 50 day moving average price is $2.06 and its 200 day moving average price is $2.43. The company’s market capitalization is $29.86 million.
Your IP Address:
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.